1Maloisel F, Dufour P, Bergerat P, et al. Results of initial doxorubicin, 5-fluorouracil,and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer, 1990,65:851-855.
2Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 1998, 16:2672-2685.
3Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol, 1999,10: 47-52.
4Brot P, Scholl SM, de la Rochefordiere A, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat, 1999, 58: 151-156.
5Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol, 1998, 16:93-100.
6Ios A, van der Hage, Cornelis JH, et al. Preoperative chemotherapy in primary operable breast cancer: results from the european organization for research and treatment of cancer trial 10902. J Clin Oncol, 2001, 19:4224-4237.
7Bonadonna G, Valagussa P, Brambilla C, et al. Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy. Semin Oncol, 1991, 18:515-524.
8Bhalla K, Harris WB. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol, 1998, 25 (2 suppl 3): 19-24.
